Evidence map›Paper›PMID 40838723›Full record

ReviewmBio2025

Rare but relevant: a comprehensive narrative review of rare HIV-1 group M subtypes.

Dana F Indihar, Rachael Oke, Rondel Hemerding, De'Travean Williams, Rupert England, Laricca Y London

Abstract readReview
In one paragraph

Review in mBio, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Dana F IndiharDepartment of Biological Sciences, Alabama A&M University, Huntsville, Alabama, USA.ORCID 0000-0002-6809-8783
Rachael OkeDepartment of Biological Sciences, Alabama A&M University, Huntsville, Alabama, USA.
Rondel HemerdingDepartment of Biological Sciences, Alabama A&M University, Huntsville, Alabama, USA.
De'Travean WilliamsDepartment of Biological Sciences, Alabama A&M University, Huntsville, Alabama, USA.
Rupert EnglandDepartment of Biological Sciences, Alabama A&M University, Huntsville, Alabama, USA.
Laricca Y LondonDepartment of Biological Sciences, Alabama A&M University, Huntsville, Alabama, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Human immunodeficiency virus type 1 (HIV-1) group M comprises 10 genetically diverse subtypes, with subtypes C and B being the most prevalent globally. However, rare subtypes F, H, J, K, and L, though individually responsible for less than 1% of HIV-1 infections worldwide, play relevant roles in viral evolution, global persistence, recombination, and drug resistance. This review provides a comprehensive synthesis of the available literature on these rare subtypes for the first time, emphasizing their distribution, recombination patterns, transmission dynamics, and drug resistance-associated mutations. A key observation is that many of these rare subtypes are more frequently found in recombinant forms than in non-recombinant forms, which may expand their geographic distribution and sustain their epidemiological presence. We further highlight drug resistance-associated mutations in the protease and reverse transcriptase regions of the rare subtypes, which may affect treatment outcomes. Advances in molecular tools, such as next-generation sequencing and Bayesian phylogeographic analyses, have improved the identification of the rare subtypes in both recombinant and non-recombinant forms. However, there remains a significant data gap in the clinical impact of these subtypes as they continue to be undersampled and understudied. This review thus underscores the need for augmenting subtype-specific surveillance strategies, especially in regions where the rare subtypes predominantly circulate. Expanding research on these rare subtypes will be essential for understanding HIV-1 recombination and evolutionary dynamics, identifying trends in drug resistance, and developing more globally inclusive anti-viral strategies that better reflect the diversity of HIV-1.

Indexed as

Genetic VariationGenotypeHIV-1HIV InfectionsAnti-HIV AgentsDrug Resistance, ViralEvolution, MolecularHumansMutationPhylogenyRecombination, GeneticAnti-HIV Agentsgenetic recombinationhuman immunodeficiency virusmultidrug resistancephylogenetic analysisrare subtypes

Identifiers

PMID40838723
PMCPMC12506054

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.